Elevidys access in Saudi Arabia: the SFDA named-patient pathway
How Saudi families with a child diagnosed with Duchenne muscular dystrophy access Elevidys (delandistrogene moxeparvovec), the AAV-based DMD gene therapy, through the SFDA Personal Importation Program and qualified pediatric neurology centers.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Elevidys (delandistrogene moxeparvovec-rokl) is an AAVrh74-based one-time gene therapy delivering a transgene encoding micro-dystrophin, approved by the US FDA on 22 June 2023 for ambulatory pediatric patients aged 4 through 5 with Duchenne muscular dystrophy, and expanded on 20 June 2024 to ambulatory patients 4 years and older and non-ambulatory patients 4 years and older with a confirmed DMD mutation. It is the first and only gene therapy approved for DMD. The drug is not currently registered with the Saudi Food and Drug Authority (SFDA) for commercial sale, so Saudi families reach it through the SFDA Personal Importation Program (PIP), prescribed by a SCFHS-licensed pediatric neurologist and dispensed by an SFDA-licensed tertiary hospital with gene-therapy infusion capability. Reserve Meds coordinates the US-side sourcing, frozen cold-chain logistics, and the documentation kit the treating pediatric neurology team needs to file with the SFDA.
Reserved for you.
Why Saudi families need Elevidys through the named-patient pathway
Duchenne muscular dystrophy is an X-linked recessive disease driven by mutations in the DMD gene. Saudi Arabia's pediatric neurology programs identify a meaningful DMD cohort each year, with the consanguinity-driven inheritance patterns of the Gulf region surfacing both Duchenne and Becker phenotypes through the major academic medical genetics services at KFSH&RC (King Faisal Specialist Hospital and Research Centre), KAMC (King Abdulaziz Medical City) within the Ministry of National Guard Health Affairs, and the major university hospitals.
The access gap for Elevidys in Saudi Arabia has four layers. First, regulatory: Sarepta has not filed Elevidys for SFDA commercial registration as of this page date. Second, certified-center capability: AAV gene therapy infusion requires a pediatric institution with infusion suite, post-infusion ICU backup, and immunomonitoring infrastructure for the post-infusion period; in Saudi Arabia this concentrates at KFSH&RC Riyadh and Jeddah and a small group of additional tertiary sites. Third, eligibility gating: anti-AAVrh74 antibody titer must be below the FDA-labeled threshold, the patient must have a confirmed DMD mutation by next-generation sequencing or MLPA, and the family must accept the boxed-warning context for serious immune-mediated myositis. Fourth, payer reality: at USD 3.2 million list price (approximately SAR 12 million at the SAR 3.75 peg), the price exceeds the per-patient ceiling on most commercial plans. Sovereign-tied institutional pathways through KFSH&RC, the Royal Court Medical Care program, or the Ministry of Health Higher Committee for Treatment Abroad may apply for select cases. Saudi Vision 2030's Health Sector Transformation Program names genomics and rare-disease care as priority verticals, which is shaping the broader funding conversation but not generating a routine reimbursement pathway at this list price.
The SFDA Personal Importation Program for Elevidys
The Saudi pathway for a KSA-licensed pediatric neurologist to obtain Elevidys is the SFDA Personal Importation Program. PIP allows a SCFHS-licensed physician to request the import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority (the US FDA for Elevidys) and a clinically equivalent locally registered alternative is not suitable. Applications are filed through the dispensing institution's import pharmacy and increasingly routed through the SFDA Ghad digital platform.
For Elevidys specifically, the clinical-justification angle that anchors the application is genetic confirmation plus institutional gene-therapy readiness. The strongest applications consistently document: a confirmed DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory (NGS report with the deletion, duplication, or point mutation specified); the patient's age (4 years or older) and ambulatory or non-ambulatory status; the baseline North Star Ambulatory Assessment (NSAA) score for ambulatory cases, or baseline upper-limb and respiratory measures for non-ambulatory cases; the anti-AAVrh74 binding antibody titer (must be below the FDA-labeled threshold per the validated assay); the immunosuppression plan for the peri-infusion period (oral prednisone or equivalent starting one day before infusion and continuing for at least 60 days); and the receiving institution's gene therapy infusion capability, pediatric critical care backup, and laboratory infrastructure for the post-infusion creatine kinase, troponin, liver function, and platelet monitoring window.
A complete PIP application includes the clinical justification letter from the treating pediatric neurologist with active SCFHS registration, the genetic test report attached as supporting documentation, the anti-AAVrh74 titer result, the proposed dosing plan at the FDA-labeled 1.33 x 10^14 vg/kg delivered as a single intravenous infusion, the destination dispensing facility license, and the chain-of-custody plan describing how the medicine will move from the Sarepta manufacturing facility through the importer to the dispensing pharmacy, including the frozen cold-chain handling at minus 60 degrees Celsius or colder. Approval timelines for routine cases at major institutions run 10 to 21 business days; complex first-time gene-therapy imports can extend to 4 to 8 weeks.
Where Elevidys gets dispensed in Saudi Arabia
The treating-center map for Elevidys in Saudi Arabia is narrower than for most named-patient drugs because of the AAV gene therapy infusion capability requirement. King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh and Jeddah hold the deepest pediatric gene therapy capability in the Kingdom and are the most likely dispensing destinations; KFSH&RC's medical genetics service handles a large share of the country's DMD diagnoses and is the natural origination point for an Elevidys conversation. King Abdulaziz Medical City (KAMC) within the Ministry of National Guard Health Affairs (MNGHA) network operates a strong pediatric specialty program. Prince Sultan Military Medical City (PSMMC) Riyadh, King Saud Medical City (KSMC) Riyadh, and King Fahad Medical City (KFMC) Riyadh participate where applicable. On the private side, Dr. Sulaiman Al Habib Medical Group, Saudi German Health, and HMG (Habib Medical Group) flagship hospitals carry import pharmacy capacity, though pediatric gene-therapy depth varies by site.
The dispensing facility must hold validated frozen storage at minus 60 degrees Celsius or colder, gene therapy infusion suite capability, pediatric critical care backup, and laboratory turnaround for the post-infusion monitoring schedule including weekly creatine kinase, troponin, AST, ALT, total bilirubin, and platelet count for the first 90 days. The receiving institution also carries the peri-infusion corticosteroid course (oral prednisone 1 mg/kg/day or equivalent starting one day before infusion, continuing for at least 60 days, with taper based on clinical and laboratory parameters).
Real cost picture for Elevidys in Saudi Arabia
US wholesale acquisition cost for Elevidys is approximately USD 3.2 million per single-dose treatment course, the highest list price for any FDA-approved gene therapy as of this page date. At the SAR 3.75 peg, the cell-product price converts to approximately SAR 12 million. This is a one-time price and reflects the entire therapy.
International logistics for the frozen shipper from the Sarepta manufacturing facility to the receiving Saudi pediatric center add a defined surcharge in the SAR 22,000 to SAR 65,000 range (USD 6,000 to USD 18,000), with customs pre-clearance handled in parallel to preserve the validated shipping window. The receiving institution's procedural and inpatient costs (gene therapy infusion suite, peri-infusion corticosteroid course, post-infusion monitoring labs across the first three months, pediatric critical care standby) are the institution's line items, not Reserve Meds'. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the payer side, Saudi insurer behavior at the USD 3.2 million price point is restrictive. Bupa Arabia, Tawuniya, and MedGulf each assess pediatric gene therapy case by case, with most commercial plans falling short of full coverage. Sovereign-tied pathways through KFSH&RC's institutional program, Royal Court Medical Care, the Ministry of Health Higher Committee for Treatment Abroad, or the Saudi Vision 2030 Health Sector Transformation rare-disease initiatives may apply for select cases. We do not promise coverage from any insurer or scheme. Cash-pay funded through family resources or institutional pathways is the operating reality for most Reserve Meds-coordinated cases.
Typical timeline for Elevidys in Saudi Arabia
SFDA routine PIP processing is typically 10 to 21 business days from a complete filing. For Elevidys specifically, the frozen shipper logistics and customs pre-clearance run in parallel with the regulatory filing rather than in sequence. End-to-end from family decision to infusion day, the typical achievable window is six to ten weeks. The anti-AAVrh74 antibody titer test result is the earliest gating event; if the titer is above the FDA-labeled threshold, the case pauses for retest consideration before the frozen shipper is staged. The peri-infusion corticosteroid course starts one day before infusion; the post-infusion monitoring window extends three months actively and longer for the structured pharmacovigilance follow-up.
What your physician needs to provide
For a Saudi-licensed pediatric neurologist prescribing Elevidys through the SFDA PIP, the clinical justification letter is the cornerstone of the application. The letter, signed with active SCFHS registration, documents the DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory (typically the KFSH&RC molecular genetics service or an accredited private lab), the patient's age (4 years or older), ambulatory or non-ambulatory status, baseline functional assessment (NSAA for ambulatory; Performance of the Upper Limb scale and respiratory measures for non-ambulatory), the anti-AAVrh74 binding antibody titer result with the validated assay named, the immunosuppression plan, and the dosing at 1.33 x 10^14 vg/kg delivered as a single intravenous infusion.
The monitoring plan covers weekly creatine kinase, troponin-I, AST, ALT, total bilirubin, and platelet count for the first 90 days, with the boxed-warning vigilance for serious immune-mediated myositis (severe muscle weakness, severe creatine kinase elevation, troponin elevation, typically within the first three months after infusion). The treating physician's SCFHS license number, the dispensing facility's license, and the pharmacy in charge of dispensing complete the package. Adverse event reporting through SFDA's National Pharmacovigilance Center is referenced in the documentation kit; reporting obligations remain with the prescribing physician and the institution.
Common questions about Elevidys in Saudi Arabia
Is Elevidys registered in Saudi Arabia? Not at this page date. Sarepta has not filed Elevidys with the SFDA for commercial registration. Access for Saudi families runs through the SFDA Personal Importation Program with US-source supply under DSCSA chain-of-custody documentation.
My son is 3 years old. Can he still receive Elevidys? The FDA label is patients 4 years and older. Under-4 cases are off-label and require a separate clinical justification not part of the standard PIP route. The treating pediatric neurology team makes the final eligibility call.
What if the anti-AAVrh74 antibody titer is too high? A titer above the FDA-labeled threshold by the validated assay is an eligibility exclusion at the time of testing. The treating pediatric neurology team determines retest cadence; in some cases titers can fall over time. If the titer remains elevated, the case typically pivots to ongoing corticosteroid therapy and supportive care.
Will Bupa Arabia, Tawuniya, or MedGulf cover the USD 3.2 million list price? Saudi insurers handle multi-million-dollar one-time gene therapies case by case. Most commercial plans have per-patient ceilings below the Elevidys list price. Sovereign-tied institutional pathways and the Royal Court Medical Care program may apply for select cases; this is a treating-institution conversation. We do not promise coverage from any source.
How does Elevidys interact with corticosteroids my son is already on? Most DMD patients in Saudi Arabia are already on long-term prednisone or deflazacort therapy. The peri-infusion corticosteroid plan layers on top of or transitions from the existing regimen, with the treating neurologist managing the overall steroid exposure. The decision sequence rests with the treating team.
What is the boxed-warning serious immune-mediated myositis? Severe muscle weakness, severe creatine kinase elevation, and troponin elevation in the first three months after infusion are the labeled risk for serious immune-mediated myositis. The receiving institution carries the weekly laboratory monitoring through the structured window, with corticosteroid escalation, IVIG, and other immunomodulation as the clinical response pathway. The family receives clear instructions on warning signs and a direct phone line to the institution between visits.
Can the medicine be administered outside Riyadh or Jeddah? The dispensing facility must hold gene therapy infusion capability, pediatric critical care backup, and validated minus 60 degrees Celsius storage. In practice this concentrates the administration at KFSH&RC Riyadh and Jeddah and a small group of other tertiary centers. Pre- and post-infusion follow-up can be coordinated with the family's home-region neurologist in coordination with the originating institution.
Where Reserve Meds fits in Elevidys cases
Reserve Meds is a US-based concierge coordinator. We do not replace your pediatric neurologist, we do not replace the SFDA, and we do not replace the receiving institution's gene therapy and critical care infrastructure. For Elevidys specifically, we orchestrate the US-side sourcing through Sarepta's qualified channel under DSCSA chain-of-custody, build the documentation kit your physician submits to the SFDA through the PIP framework, coordinate frozen cold-chain logistics with continuous temperature logging into Saudi Arabia, pre-stage customs clearance in parallel with regulatory filing, and assign a single named coordinator through the case. The clinical decisions remain with the treating pediatric neurology and gene therapy team; the regulatory authority remains the SFDA; the gene therapy delivery remains with the qualified Saudi institution.
Next step
If your pediatric neurologist has diagnosed DMD in your son and you are weighing the Elevidys cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.